Menarini Group and Radius Health Announce Positive Phase 3 Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer
October 20, 2021 08:30 ET
|
Radius Health Inc.; Menarini Group
Study met both primary endpoints in patients with ER+/HER2- advanced or mBCElacestrant becomes the first oral SERD with positive topline results in pivotal study as a monotherapy versus SoC for the...
Radius Announces Positive Phase 3 Topline Results for TYMLOS® (abaloparatide) Subcutaneous Injection in Males with Osteoporosis
October 18, 2021 08:30 ET
|
Radius Health Inc.
ATOM study met the primary endpoint of change in lumbar spine bone mineral density at 12 months (p-value < 0.0001)Study also met secondary endpoints relating to bone mineral density changes in...
TYMLOS Label and Business Update
September 22, 2021 08:00 ET
|
Radius Health Inc.
TYMLOS® label: significant update to the Mechanism of Action (MOA) sectionLabel change aligns with strategic focus on postmenopausal women at high risk of fractureDanielle Holtschlag joins as Head of...
Radius Health, Inc.: Second Quarter and Year-to-Date Results
August 05, 2021 07:00 ET
|
Radius Health Inc.
Repositioned the Company to create meaningful P+L operating leverageDramatic improvement in Adj. EBITDA performance: ($6) million in Q2, 2021 vs. ($29) million in Q2, 2020FY 2021 guidance: reiterate...
Radius Health Business Update
July 27, 2021 08:00 ET
|
Radius Health Inc.
Added 5,000+ new TYMLOS patients in Q2, 2021, up 40+% vs. Q2, 2020 and 3% vs. Q1, 2021ATOM and wearABLe abaloparatide Phase 3 trial readouts remain on track for 2H, 2021EU abaloparatide regulatory...
CORRECTION: Radius Health Announces Plans for Global Prader-Willi Syndrome Pivotal Study
July 23, 2021 11:12 ET
|
Radius Health Inc.
FDA Type C meeting minutes provide clarity on the Phase 2/3 study design for RAD011505(b)(2) regulatory strategy: acceptable approach upon completion of PK & food effect studiesBased on results, a...
Radius Health Announces Plans for Global Prader-Willi Syndrome Pivotal Study
July 22, 2021 09:00 ET
|
Radius Health Inc.
FDA Type C meeting minutes provide clarity on the Phase 2/3 study design for RAD011505(b)(2) regulatory strategy: acceptable approach upon completion of PK & food effect studiesBased on results, a...
Radius Health to Announce Second Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Thursday, August 5, 2021
July 20, 2021 17:11 ET
|
Radius Health Inc.
BOSTON, July 20, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) announced today that it will release its second quarter financial results on Thursday, August 5, 2021. The Company will...
Radius Health Business Update
June 02, 2021 08:15 ET
|
Radius Health Inc.
TYMLOS® new patient adds in April: modest growth vs. previous 4-month trailing averages~67% of new patients in April were initiated by a fracture focused bone health accountMeaningful FDA guidance on...
Radius Health, Inc.: First Quarter 2021 Results
May 07, 2021 06:30 ET
|
Radius Health Inc.
Total net revenue: $56 million vs. $48 million in Q1, 2020, +17% year-over-yearTYMLOS® U.S. product net revenue: $45 million vs. $48 million in Q1, 2020, -6% year-over-yearSignificant operating...